Sign In
Buy MPLN
$23.15
+0 (+0%)
At Close: May 23, 2025
ClearNote Health's Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev's National PPO Networks
08:03am, Wednesday, 12'th Mar 2025
SAN DIEGO--(BUSINESS WIRE)-- #5hmC--ClearNote Health's Avantect Pancreatic Cancer Test will now be available to members accessing Claritev's national PHCS and MultiPlan Networks.
Claritev Corporation (MPLN) Q4 2024 Earnings Call Transcript
04:36pm, Tuesday, 25'th Feb 2025
Claritev Corporation (MPLN) Q4 2024 Earnings Call Transcript
MultiPlan Corporation (MPLN) Reports Q4 Loss, Misses Revenue Estimates
08:20am, Tuesday, 25'th Feb 2025
MultiPlan Corporation (MPLN) came out with a quarterly loss of $5.14 per share versus the Zacks Consensus Estimate of a loss of $2.33. This compares to loss of $2.40 per share a year ago.
Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025
06:00am, Tuesday, 25'th Feb 2025
NEW YORK--(BUSINESS WIRE)--Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025.
Claritev Provides Oracle Cloud HCM Customers with Actionable Insights for Healthcare Cost Optimization and Plan Design
08:00am, Friday, 21'st Feb 2025
NEW YORK--(BUSINESS WIRE)---- $MPLN #MPLN--Claritev Corporation (“Claritev” or the “Company”) (NYSE: MPLN), formerly known as MultiPlan, a technology, data and insights company focused on maki
NEW YORK--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare mo
MultiPlan Corporation Announces Fourth Quarter and Full Year 2024 Earnings Conference Call
08:30am, Tuesday, 28'th Jan 2025
NEW YORK--(BUSINESS WIRE)--MultiPlan Corporation Announces Fourth Quarter and Full Year 2024 Earnings Conference Call.
NEW YORK--(BUSINESS WIRE)---- $MPLN #MPLN--MultiPlan Corporation (NYSE: MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data solutions focused on cost management, im
MultiPlan (MPLN) Soars 15.5%: Is Further Upside Left in the Stock?
04:50am, Tuesday, 14'th Jan 2025
MultiPlan (MPLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
MultiPlan Selects Oracle Cloud Infrastructure to Power its Business Transformation
08:00am, Monday, 13'th Jan 2025
NEW YORK--(BUSINESS WIRE)---- $MPLN #MPLN--MultiPlan Corporation (NYSE: MPLN), a leading provider of technology and data solutions that improve affordability, quality and transparency in healthcare, w
MultiPlan and J2 Health Announce Strategic Agreement to Enhance Network Services and Analytics
12:30pm, Friday, 10'th Jan 2025
NEW YORK--(BUSINESS WIRE)---- $MPLN #MPLN--MultiPlan Corporation (“MultiPlan” or the “Company”) (NYSE: MPLN), a leading provider of technology and data solutions that improve affordability, qu
MultiPlan Announces Comprehensive Refinancing
09:00am, Tuesday, 24'th Dec 2024
NEW YORK--(BUSINESS WIRE)---- $MPLN #MPLN--MultiPlan Corporation (NYSE: MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data solutions focused on cost management, im
MultiPlan Announces Commencement of Exchange Offers and Consent Solicitations for Outstanding Notes
09:00am, Tuesday, 24'th Dec 2024
NEW YORK--(BUSINESS WIRE)---- $MPLN #MPLN--MultiPlan Corporation (NYSE: MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data solutions focused on cost management, im
MultiPlan Corporation (MPLN) Q3 2024 Earnings Conference Call Transcript
02:35pm, Tuesday, 05'th Nov 2024
MultiPlan Corporation (NYSE:MPLN ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Shawna Gasik - AVP, IR Travis Dalton - CEO Doug Garis - CFO Conference Call Partici
MultiPlan Corporation (MPLN) Reports Q3 Loss, Lags Revenue Estimates
08:16am, Tuesday, 05'th Nov 2024
MultiPlan Corporation (MPLN) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.37. This compares to loss of $2.40 per share a year ago.
